成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

  2. Stem Cell/Wnt Apoptosis
  3. β-catenin Apoptosis
  4. ICG-001

ICG-001 是 β-catenin/TCF 介導的轉(zhuǎn)錄抑制劑。 ICG-001 特異性結(jié)合 CREB 蛋白起作用，IC50 為3 μM。ICG-001 選擇性地阻斷 β-catenin/CBP 相互作用而不干擾 β-catenin/p300 相互作用。

MCE 的所有產(chǎn)品僅用作科學研究或藥證申報，我們不為任何個人用途提供產(chǎn)品和服務

ICG-001 Chemical Structure

ICG-001 Chemical Structure

CAS No. : 780757-88-2

1.  客戶無需承擔相應的運輸費用。

2.  同一機構(gòu)（單位）同一產(chǎn)品試用裝僅限申領一次，同一機構(gòu)（單位）一年內(nèi)

     可免費申領三個不同產(chǎn)品的試用裝。

3.  試用裝只面向終端客戶。

規(guī)格 價格 是否有貨 數(shù)量
10 mM * 1 mL in DMSO ￥1112
In-stock
5 mg ￥921
In-stock
10 mg ￥1200
In-stock
50 mg ￥4500
In-stock
100 mg 現(xiàn)貨 詢價
200 mg   詢價  
500 mg   詢價  

* Please select Quantity before adding items.

Customer Review

MCE 顧客使用本產(chǎn)品發(fā)表的 47 篇科研文獻

WB
IHC

    ICG-001 purchased from MCE. Usage Cited in: Cell Death Dis. 2018 Jul 18;9(8):793.  [Abstract]

    BMDMs are cultured with the conditional medium (CM) that is collected from cultured Hepa1-6 cells for 24?h. Meanwhile BMDMs are treated with or without ICG001. The M2-related markers and downstream genes of Wnt signaling are detected by western blotting.

    ICG-001 purchased from MCE. Usage Cited in: Int J Mol Sci. 2018 Jul 6;19(7). pii: E1981.  [Abstract]

    Cells exposed to ICG-001 for 24 h under different concentrations of (0, 6, 8 μM) are analyzed by Western blot for full-length PARP and cleaved PARP, with β-actin being a loading control.

    ICG-001 purchased from MCE. Usage Cited in: J Exp Clin Cancer Res. 2017 Sep 11;36(1):125.  [Abstract]

    ICG-001 mediates the association of β-catenin with CBP, P300, E-cadherin and N-cadherin. a and b Western blotting analysis of Wnt related proteins from total proteins and extracted nuclear and cytoplasmic proteins.

    ICG-001 purchased from MCE. Usage Cited in: Oncotarget. 2017 Dec 1;8(70):115089-115101.  [Abstract]

    ICG001 normalizes the down expression of E-cadherin and reduces the over-expression of N-cadherin and snail in residual tumor tissue after insufficient microwave ablation (MWA).

    ICG-001 purchased from MCE. Usage Cited in: Oncotarget. 2017 Dec 1;8(70):115089-115101.  [Abstract]

    ICG001 depresses the heat-induced over-expression of EMT markers (N-cadherin, Snail), and partially recovers the expression of E-cadherin in heat-treated SUM-1315 and ZR-75-1 cells.

    ICG-001 purchased from MCE. Usage Cited in: Cancer Sci. 2016 Dec;107(12):1776-1784.  [Abstract]

    The amount of ABCC3 protein is increased by ICG-001 treatment in HT-29 cells.

    • 生物活性

    • 實驗參考方法

    • 純度 & 產(chǎn)品資料

    • 參考文獻

    生物活性

    ICG-001 is an inhibitor of β-catenin/TCF mediated transcription. ICG-001 works by specifically binding to cyclic AMP response element-binding protein with an IC50 of 3 μM. ICG-001 selectively blocks the β-catenin/CBP interaction without interfering with the β-catenin/p300 interaction.

    IC50 & Target

    IC50: 3 μM (CBP)
    細胞效力
    (Cellular Effect)
    Cell Line Type Value Description References
    A549 GI50
    6.1 μM
    Compound: ICG001
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 24950489]
    HCT-116 IC50
    38 μM
    Compound: ICG-001
    Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition measured after 72 hrs by MTS assay
    Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition measured after 72 hrs by MTS assay
    		[PMID: 34382808]
    HCT-116 IC50
    38 μM
    Compound: ICG-001
    Antiproliferative activity against beta-catenin signalling overexpressing human HCT-116 cells assessed as reduction in cell growth incubated for 72 hrs by MTS assay
    Antiproliferative activity against beta-catenin signalling overexpressing human HCT-116 cells assessed as reduction in cell growth incubated for 72 hrs by MTS assay
    		[PMID: 34270257]
    HepG2 GI50
    12.7 μM
    Compound: ICG001
    Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
    		[PMID: 24950489]
    HT-29 IC50
    10.8 μM
    Compound: ICG-001
    Cytotoxicity against human HT-29 cells assessed as cell viability at 1.563 to 50 uM measured after 72 hrs by plate reader method
    Cytotoxicity against human HT-29 cells assessed as cell viability at 1.563 to 50 uM measured after 72 hrs by plate reader method
    		[PMID: 34062253]
    HT-29 GI50
    17.2 μM
    Compound: ICG001
    Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay
    		[PMID: 24950489]
    HT-29 IC50
    18.7 μM
    Compound: ICG001
    Inhibition of Wnt signaling in human HT29 cells assessed as inhibition of beta-catenin-mediated Tcf/Lef transcriptional activity after 24 hrs by dual luciferase reporter gene assay relative to control
    Inhibition of Wnt signaling in human HT29 cells assessed as inhibition of beta-catenin-mediated Tcf/Lef transcriptional activity after 24 hrs by dual luciferase reporter gene assay relative to control
    		[PMID: 24950489]
    LoVo GI50
    15.6 μM
    Compound: ICG001
    Antiproliferative activity against human LoVo cells after 72 hrs by MTT assay
    Antiproliferative activity against human LoVo cells after 72 hrs by MTT assay
    		[PMID: 24950489]
    MCF-10A IC50
    21 μM
    Compound: ICG-001
    Cytotoxicity against human MCF-10A cells assessed as cell growth inhibition measured after 72 hrs by MTS assay
    Cytotoxicity against human MCF-10A cells assessed as cell growth inhibition measured after 72 hrs by MTS assay
    		[PMID: 34382808]
    MCF-10A IC50
    21 μM
    Compound: ICG-001
    Cytotoxicity against human MCF-10A cells assessed as reduction in cell growth incubated for 72 hrs by MTS assay
    Cytotoxicity against human MCF-10A cells assessed as reduction in cell growth incubated for 72 hrs by MTS assay
    		[PMID: 34270257]
    MDA-MB-231 IC50
    7.2 μM
    Compound: ICG-001
    Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 72 hrs by MTS assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 72 hrs by MTS assay
    		[PMID: 34382808]
    MDA-MB-231 IC50
    7.2 μM
    Compound: ICG-001
    Antiproliferative activity against beta-catenin signalling overexpressing human MDA-MB-231 cells assessed as reduction in cell growth incubated for 72 hrs by MTS assay
    Antiproliferative activity against beta-catenin signalling overexpressing human MDA-MB-231 cells assessed as reduction in cell growth incubated for 72 hrs by MTS assay
    		[PMID: 34270257]
    MDA-MB-468 IC50
    31 μM
    Compound: ICG-001
    Antiproliferative activity against human MDA-MB-468 cells assessed as cell growth inhibition measured after 72 hrs by MTS assay
    Antiproliferative activity against human MDA-MB-468 cells assessed as cell growth inhibition measured after 72 hrs by MTS assay
    		[PMID: 34382808]
    MDA-MB-468 IC50
    31 μM
    Compound: ICG-001
    Antiproliferative activity against beta-catenin signalling overexpressing human MDA-MB-468 cells assessed as reduction in cell growth incubated for 72 hrs by MTS assay
    Antiproliferative activity against beta-catenin signalling overexpressing human MDA-MB-468 cells assessed as reduction in cell growth incubated for 72 hrs by MTS assay
    		[PMID: 34270257]
    SW480 IC50
    1.3 μM
    Compound: ICG-001
    Inhibition of CBP binding to beta-casein in human SW480 cells by immunoblot analysis
    Inhibition of CBP binding to beta-casein in human SW480 cells by immunoblot analysis
    		[PMID: 23232060]
    SW480 IC50
    6.1 μM
    Compound: ICG-001
    Antiproliferative activity against human SW480 cells assessed as cell growth inhibition measured after 72 hrs by MTS assay
    Antiproliferative activity against human SW480 cells assessed as cell growth inhibition measured after 72 hrs by MTS assay
    		[PMID: 34382808]
    SW480 IC50
    6.1 μM
    Compound: ICG-001
    Antiproliferative activity against beta-catenin signalling overexpressing human SW480 cells assessed as reduction in cell growth incubated for 72 hrs by MTS assay
    Antiproliferative activity against beta-catenin signalling overexpressing human SW480 cells assessed as reduction in cell growth incubated for 72 hrs by MTS assay
    		[PMID: 34270257]
    體外研究
    (In Vitro)

    ICG-001 (5 μM) 在 MCF7 細胞中抑制瘦素誘導的 EMT、侵襲和腫瘤球形成[1]。ICG-001 可以在表型上挽救早老素 1 突變細胞中正常神經(jīng)生長因子 (NGF) 誘導的神經(jīng)元分化和神經(jīng)元向外生長，強調(diào)了 TCF/β-catenin 信號通路對神經(jīng)突向外生長和神經(jīng)元分化的重要性[2]。ICG-001 (25 μM) 處理可降低 SW480 細胞中生存素和細胞周期蛋白 D1 RNA 和蛋白質(zhì)的穩(wěn)態(tài)水平，這兩者均可被 β-連環(huán)蛋白上調(diào)。ICG-001 在轉(zhuǎn)化細胞而非正常結(jié)腸細胞中選擇性誘導細胞凋亡，并減少結(jié)腸癌細胞的體外生長[3]。

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    體內(nèi)研究
    (In Vivo)

    ICG-001 (每天 5 mg/kg) 顯著抑制小鼠的 β-連環(huán)蛋白信號傳導，同時保護上皮細胞[2]。施用 ICG-001 的水溶性類似物 9 周后，結(jié)腸和小腸息肉的形成減少了 42%，與非甾體類抗炎藥 MK-231 一樣有效，后者在該模型中一直顯示出療效。ICG-001 (150 mg/kg，靜脈注射) 在 SW620 裸鼠腫瘤消退異種移植模型中顯示，在 19 天的處理過程中腫瘤體積顯著減少，沒有死亡或體重減輕[3]。

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    分子量

    548.63

    Formula

    C33H32N4O4
    CAS 號
    性狀

    固體

    顏色

    White to off-white

    運輸條件

    Room temperature in continental US; may vary elsewhere.
    儲存方式
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 2 years
    -20°C 1 year
    溶解性數(shù)據(jù)
    細胞實驗： 

    DMSO 中的溶解度 : ≥ 50 mg/mL (91.14 mM; 吸濕的 DMSO 對產(chǎn)品的溶解度有顯著影響，請使用新開封的 DMSO)

    * "≥" means soluble, but saturation unknown.

    配制儲備液
    濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg
    1 mM 1.8227 mL 9.1136 mL 18.2272 mL
    5 mM 0.3645 mL 1.8227 mL 3.6454 mL
    查看完整儲備液配制表

    * 請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；一旦配成溶液，請分裝保存，避免反復凍融造成的產(chǎn)品失效。
    儲備液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C儲存時，請在2年內(nèi)使用， -20°C儲存時，請在1年內(nèi)使用。

    • 摩爾計算器

    • 稀釋計算器

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    質(zhì)量
    =
    濃度
    ×
    體積
    ×
    分子量 *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    濃度 (start)

    C1

    ×
    體積 (start)

    V1

    =
    濃度 (final)

    C2

    ×
    體積 (final)

    V2

    動物實驗：

    請根據(jù)您的 實驗動物和給藥方式 選擇適當?shù)娜芙夥桨浮?

    以下溶解方案都請先按照 In Vitro 方式配制澄清的儲備液，再依次添加助溶劑：
    ——為保證實驗結(jié)果的可靠性，澄清的儲備液可以根據(jù)儲存條件，適當保存；體內(nèi)實驗的工作液，建議您現(xiàn)用現(xiàn)配，當天使用；
    以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶

    • 方案 一

      請依序添加每種溶劑： 10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.5 mg/mL (4.56 mM); 澄清溶液

      此方案可獲得 ≥ 2.5 mg/mL（飽和度未知）的澄清溶液。

      以 1 mL 工作液為例，取 100 μL 25.0 mg/mL 的澄清 DMSO 儲備液加到 400 μL PEG300 中，混合均勻；再向上述體系中加入 50 μL Tween-80，混合均勻；然后再繼續(xù)加入 450 μL 生理鹽水 定容至 1 mL。

      生理鹽水的配制：將 0.9 g 氯化鈉，溶解于 ddH?O 并定容至 100 mL，可以得到澄清透明的生理鹽水溶液。
    • 方案 二

      請依序添加每種溶劑： 10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: 2.5 mg/mL (4.56 mM); 懸濁液; 超聲加熱助溶

      此方案可獲得 2.5 mg/mL的均勻懸濁液，懸濁液可用于口服和腹腔注射。

      以 1 mL 工作液為例，取 100 μL 25.0 mg/mL 的澄清 DMSO 儲備液加到 900 μL 20% 的 SBE-β-CD 生理鹽水水溶液 中，混合均勻。

      2 g SBE-β-CD（磺丁基醚 β-環(huán)糊精）粉末定容于 10 mL 的生理鹽水中，完全溶解至澄清透明。

    以下溶解方案，請直接配制工作液。建議現(xiàn)用現(xiàn)配，在短期內(nèi)盡快用完。 以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比； 如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶。

    • 方案 一

      請依序添加每種溶劑： 15% Cremophor EL    85% Saline

      Solubility: 1.67 mg/mL (3.04 mM); 懸濁液; 超聲助溶

    • 方案 二

      請依序添加每種溶劑： 17% Solutol HS-15 in Saline

      Solubility: 1.67 mg/mL (3.04 mM); 懸濁液; 超聲助溶

    動物溶解方案計算器
    請輸入動物實驗的基本信息：

    給藥劑量

    mg/kg

    動物的平均體重

    g

    每只動物的給藥體積

    μL

    動物數(shù)量

    只
    由于實驗過程有損耗，建議您多配一只動物的量
    請輸入您的動物體內(nèi)配方組成：
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    如果您的動物是免疫缺陷鼠或者體弱鼠，建議 DMSO 中的在最后工作液體系中的占比盡量不超過 2%。
    方案所需 助溶劑 包括：DMSO， ，均可在 MCE 網(wǎng)站選購。 ，Tween 80，均可在 MCE 網(wǎng)站選購。
    計算結(jié)果
    工作液所需濃度 : mg/mL
    儲備液配制方法 : mg 藥物溶于 μL  DMSO（母液濃度為 mg/mL）。
    您所需的儲備液濃度超過該產(chǎn)品的實測溶解度，以下方案僅供參考，如有需要，請與 MCE 中國技術(shù)支持聯(lián)系。
    動物實驗體內(nèi)工作液的配制方法 : 取 μL DMSO 儲備液，加入 μL 。 μL ，混合均勻至澄清，再加 μL Tween 80，混合均勻至澄清，再加 μL 生理鹽水。
    連續(xù)給藥周期超過半月以上，請謹慎選擇該方案。
    請確保第一步儲備液溶解至澄清狀態(tài)，從左到右依次添加助溶劑。您可采用超聲加熱 （超聲清洗儀，建議頻次 20-40 kHz），渦旋吹打等方式輔助溶解。
    純度 & 產(chǎn)品資料

    純度: 99.86%

    參考文獻
    Cell Assay
    [2]

    To evaluate effects of ICG-001 on α-SMA and collagen type 1 expression, RLE-6TN cells are treated with TGF-β1 (0.25 ng/mL) in the presence or absence of ICG-001 (5.0 μM). After 24 h, cells are harvested and mRNA isolated for analysis by qPCR. RNA is reverse-transcribed using SuperScript reverse transcriptase. Quantitative PCR is performed with SYBR-Green PCR using Real-Time PCR System HT7900. The amplification protocol is set as follows: 95°C denaturation for 10 min followed by 40 cycles of 15-s denaturation at 95°C, 1 min of annealing/extension, and data collection at 60°C.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    Animal Administration
    [3]

    Seven-week-old male C57BL/6J-ApcMin/+and WT C57BL/6J mice are treated orally for 9 weeks with ICG-001a (300 mg/kg per day) or vehicle (1% carboxymethylcellulose), once daily, six times per week. MK-231 is administered in drinking water (160 ppm, dissolved in 8 mM Na2PO4 buffer, pH 7.6). At 16 weeks, the polyp number is counted manually by using a dissecting microscope.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    參考文獻

    完整儲備液配制表

    * 請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；一旦配成溶液，請分裝保存，避免反復凍融造成的產(chǎn)品失效。
    儲備液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C儲存時，請在2年內(nèi)使用， -20°C儲存時，請在1年內(nèi)使用。

    可選溶劑 濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 1.8227 mL 9.1136 mL 18.2272 mL 45.5681 mL
    5 mM 0.3645 mL 1.8227 mL 3.6454 mL 9.1136 mL
    10 mM 0.1823 mL 0.9114 mL 1.8227 mL 4.5568 mL
    15 mM 0.1215 mL 0.6076 mL 1.2151 mL 3.0379 mL
    20 mM 0.0911 mL 0.4557 mL 0.9114 mL 2.2784 mL
    25 mM 0.0729 mL 0.3645 mL 0.7291 mL 1.8227 mL
    30 mM 0.0608 mL 0.3038 mL 0.6076 mL 1.5189 mL
    40 mM 0.0456 mL 0.2278 mL 0.4557 mL 1.1392 mL
    50 mM 0.0365 mL 0.1823 mL 0.3645 mL 0.9114 mL
    60 mM 0.0304 mL 0.1519 mL 0.3038 mL 0.7595 mL
    80 mM 0.0228 mL 0.1139 mL 0.2278 mL 0.5696 mL
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    您最近查看的產(chǎn)品:

    Your information is safe with us. * Required Fields.

       產(chǎn)品名稱：

    		  

    * 需求量：

    * 客戶姓名：

    		 

    * Email：

    * 電話：

    		 

    * 公司或機構(gòu)名稱：

       留言給我們：

    Bulk Inquiry

    Inquiry Information

    產(chǎn)品名稱：
    ICG-001
    目錄號：
    HY-14428
    需求量：